BEAM-302

DRUG2 trials

Sponsors

Beam Therapeutics Inc.

Conditions

Alpha 1-Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Phase 1

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

RecruitingNCT06389877

Beam Therapeutics Inc.Alpha 1-Antitrypsin Deficiency

Start: 2024-06-19End: 2030-05-01Target: 106Updated: 2026-03-20

A Phase 1/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

RecruitingCTIS2023-509256-34-00

Beam Therapeutics Inc.Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease

Start: 2025-02-06Target: 34Updated: 2025-12-08